MOLN
HEALTHCAREMolecular Partners AG
$4.29+0.04 (+0.83%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MOLN Today?
No stock-specific AI insight has been generated for MOLN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.41$5.36
$4.29
Fundamentals
Market Cap$160M
P/E Ratio—
EPS$-2.11
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume2K
Avg Volume (10D)—
Shares Outstanding37.4M
MOLN News
20 articles- Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferencesGlobeNewswire Inc.·May 4, 2026
- Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingYahoo Finance·May 1, 2026
- Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712Yahoo Finance·Apr 19, 2026
- Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General MeetingGlobeNewswire Inc.·Apr 14, 2026
- 3 European Penny Stocks With Market Caps Under €600MYahoo Finance·Apr 6, 2026
- Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of DirectorsYahoo Finance·Mar 23, 2026
- Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple IsotopesYahoo Finance·Mar 19, 2026
- Molecular Partners to Hold Three Poster Presentations at AACR 2026Yahoo Finance·Mar 17, 2026
- Molecular Partners Reports Highlights and Financial Results for Full Year 2025Yahoo Finance·Mar 12, 2026
- Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial ResultsYahoo Finance·Feb 26, 2026
- Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha RadiotherapeuticsYahoo Finance·Feb 26, 2026
- Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II ReadyMarketbeat·Feb 2, 2026
- Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026Yahoo Finance·Feb 2, 2026
- Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 11, 2026
- Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Dec 18, 2025
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted RadiotherapeuticsYahoo Finance·Dec 11, 2025
- Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual MeetingYahoo Finance·Dec 7, 2025
- Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of ActionYahoo Finance·Nov 12, 2025
- Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025Yahoo Finance·Nov 3, 2025
- Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual MeetingYahoo Finance·Nov 3, 2025
All 20 articles loaded
Price Data
Open$4.20
Previous Close$4.25
Day High$4.29
Day Low$4.20
52 Week High$5.36
52 Week Low$3.41
52-Week Range
$3.41$5.36
$4.29
Fundamentals
Market Cap$160M
P/E Ratio—
EPS$-2.11
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume2K
Avg Volume (10D)—
Shares Outstanding37.4M
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—